Fentanyl and its derivatives: Pain-killers or man-killers?
Status PubMed-not-MEDLINE Language English Country England, Great Britain Media electronic-ecollection
Document type Journal Article, Review
PubMed
38644874
PubMed Central
PMC11031787
DOI
10.1016/j.heliyon.2024.e28795
PII: S2405-8440(24)04826-6
Knihovny.cz E-resources
- Keywords
- Drug overdose, Fentanyl, Fentanyl derivatives, Opioid epidemic, Pharmacology, Toxicology,
- Publication type
- Journal Article MeSH
- Review MeSH
Fentanyl is a synthetic μ-opioid receptor agonist approved to treat severe to moderate pain with faster onset of action and about 100 times more potent than morphine. Over last two decades, abuse of fentanyl and its derivatives has an increased trend, globally. Currently, the United States (US) faces the most serious situation related to fentanyl overdose, commonly referred to as the opioid epidemic. Nowadays, fentanyl is considered as the number one cause of death for adults aged 18-45 in the US. Synthesis and derivatization of fentanyl is inexpensive to manufacture and easily achievable. Indeed, more than 1400 fentanyl derivatives have been described in the scientific literature and patents. In addition, accessibility and efficacy of fentanyl and its derivatives can play a potential role in misuse of these compounds as a chemical weapon. In this review, the properties, general pharmacology, and overdose death cases associated with fentanyl and selected derivatives are presented. Moreover, current opioid epidemic in the US, Moscow theatre hostage crisis, and potential misuse of fentanyl and its derivatives as a chemical weapon are disclosed.
NBC Defence Institute University of Defence 68201 Vyskov Czech Republic
Philosophical Faculty University of Hradec Kralove 50003 Hradec Kralove Czech Republic
School of Food and Biological Engineering Hefei University of Technology Hefei 230009 China
See more in PubMed
Hansen M.S., Mathiesen O., Trautner S., Dahl J.B. Intranasal fentanyl in the treatment of acute pain--a systematic review. Acta Anaesthesiol. Scand. 2012;56:407–419. doi: 10.1111/j.1399-6576.2011.02613.x. PubMed DOI
Peterson A.B. Increases in fentanyl-related overdose deaths — Florida and Ohio, 2013–2015. MMWR Morb. Mortal. Wkly. Rep. 2016;65:844–849. doi: 10.15585/mmwr.mm6533a3. PubMed DOI
CDC Products - vital Statistics rapid release - provisional drug overdose data. 2022. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
Pichini S., Solimini R., Berretta P., Pacifici R., Busardò F.P. Acute intoxications and fatalities from illicit fentanyl and analogues: an update. Ther. Drug Monit. 2018;40:38–51. doi: 10.1097/FTD.0000000000000465. PubMed DOI
Fodale V., Mafrica F., Santamaria L.B., Coleman J.J. Killer fentanyl: is the fear justified? Expet Opin. Drug Saf. 2008;7:213–217. doi: 10.1517/14740338.7.3.213. PubMed DOI
Kuczyńska K., Grzonkowski P., Kacprzak Ł., Zawilska J.B. Abuse of fentanyl: an emerging problem to face. Forensic Sci. Int. 2018;289:207–214. doi: 10.1016/j.forsciint.2018.05.042. PubMed DOI
Jannetto P.J., Helander A., Garg U., Janis G.C., Goldberger B., Ketha H. The fentanyl epidemic and evolution of fentanyl analogs in the United States and the European union. Clin. Chem. 2019;65:242–253. doi: 10.1373/clinchem.2017.281626. PubMed DOI
Allen L.V., Stiles M.L., Tu Y.H. Stability of fentanyl citrate in 0.9% sodium chloride solution in portable infusion pumps. Am. J. Hosp. Pharm. 1990;47:1572–1574. PubMed
Donnelly R.F. Chemical stability of fentanyl in polypropylene syringes and polyvinylchloride bags. Int. J. Pharm. Compd. 2005;9:482–483. PubMed
Moffat A.C. fourth ed. London Pharmaceutical Press; 2011. Clarke's Analysis of Drugs and Poisons in Pharmaceuticals, Body Fluids and Postmortem Material.http://library.lincoln.ac.uk/items/119309
Choińska M.K., Šestáková I., Hrdlička V., Skopalová J., Langmaier J., Maier V., Navrátil T. Electroanalysis of fentanyl and its new analogs: a review. Biosensors. 2022;12:26. doi: 10.3390/bios12010026. PubMed DOI PMC
Thurlkill R.L., Cross D.A., Scholtz J.M., Pace C.N. pKa of fentanyl varies with temperature: implications for acid-base management during extremes of body temperature. J. Cardiothorac. Vasc. Anesth. 2005;19:759–762. doi: 10.1053/j.jvca.2004.11.039. PubMed DOI
Peng P.W.H., Sandler A.N. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology. 1999;90:576–599. doi: 10.1097/00000542-199902000-00034. PubMed DOI
Stanley T.H. The fentanyl story. J. Pain. 2014;15:1215–1226. doi: 10.1016/j.jpain.2014.08.010. PubMed DOI
Gupta P.K., Manral L., Ganesan K., Malhotra R.C., Sekhar K. 2013. Method for the Preparation of Fentanyl. US8399677B2.
Rosenbaum D.M., Rasmussen S.G.F., Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356–363. doi: 10.1038/nature08144. PubMed DOI PMC
Feng Y., He X., Yang Y., Chao D., Lazarus L.H., Xia Y. Current research on opioid receptor function. Curr. Drug Targets. 2012;13:230–246. PubMed PMC
Dhaliwal A., Gupta M. StatPearls Publishing; Treasure Island (FL): 2021. Physiology, Opioid Receptor, in: StatPearls.http://www.ncbi.nlm.nih.gov/books/NBK546642/ PubMed
Borsodi A., Bruchas M., Caló G., Chavkin C., Christie M.J., Civelli O., Connor M., Cox B.M., Devi L.A., Evans C., Höllt V., Henderson G., Husbands S., Kelly E., Kieffer B., Kitchen I., Kreek M.-J., Liu-Chen L.-Y., Massot D., Meunier J.-C., Portoghese P.S., Schulz S., Shippenberg T.S., Simon E.J., Toll L., Traynor J.R., Ueda H., Wong Y.H., Zaveri N., Zimmer A. Opioid receptors in GtoPdb v.2021.3, IUPHAR/BPS guide to pharmacology CITE. 2021. 2021. DOI
Chen J.C., Smith E.R., Cahill M., Cohen R., Fishman J.B. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 1993;52:389–396. doi: 10.1016/0024-3205(93)90152-s. PubMed DOI
Eshleman A.J., Nagarajan S., Wolfrum K.M., Reed J.F., Nilsen A., Torralva R., Janowsky A. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors. Biochem. Pharmacol. 2020;182 doi: 10.1016/j.bcp.2020.114293. PubMed DOI
Al-Hasani R., Bruchas M.R. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115:1363–1381. doi: 10.1097/ALN.0b013e318238bba6. PubMed DOI PMC
Schmid C.L., Kennedy N.M., Ross N.C., Lovell K.M., Yue Z., Morgenweck J., Cameron M.D., Bannister T.D., Bohn L.M. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. 2017;171:1165–1175.e13. doi: 10.1016/j.cell.2017.10.035. PubMed DOI PMC
Pineyro G., Nagi K. Signaling diversity of mu- and delta- opioid receptor ligands: Re-evaluating the benefits of β-arrestin/G protein signaling bias. Cell. Signal. 2021;80 doi: 10.1016/j.cellsig.2020.109906. PubMed DOI
Neve J.D., Barlow T.M.A., Tourwé D., Bihel F., Simonin F., Ballet S. Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors. RSC Med. Chem. 2021;12:828–870. doi: 10.1039/D1MD00041A. PubMed DOI PMC
Azzam A.A.H., McDonald J., Lambert D.G. Hot topics in opioid pharmacology: mixed and biased opioids. Br. J. Anaesth. 2019;122:e136–e145. doi: 10.1016/j.bja.2019.03.006. PubMed DOI
Bateman J.T., Levitt E.S. Evaluation of G protein bias and β-arrestin 2 signaling in opioid-induced respiratory depression. Am. J. Physiol. Cell Physiol. 2021;321:C681–C683. doi: 10.1152/ajpcell.00259.2021. PubMed DOI PMC
Lemel L., Lane J.R., Canals M. GRKs as key modulators of opioid receptor function. Cells. 2020;9:2400. doi: 10.3390/cells9112400. PubMed DOI PMC
Chen Y.-J., Oldfield S., Butcher A.J., Tobin A.B., Saxena K., Gurevich V.V., Benovic J.L., Henderson G., Kelly E. Identification of phosphorylation sites in the COOH-terminal tail of the μ-opioid receptor. J. Neurochem. 2013;124:189–199. doi: 10.1111/jnc.12071. PubMed DOI PMC
Just S., Illing S., Trester-Zedlitz M., Lau E.K., Kotowski S.J., Miess E., Mann A., Doll C., Trinidad J.C., Burlingame A.L., von Zastrow M., Schulz S. Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol. Pharmacol. 2013;83:633–639. doi: 10.1124/mol.112.082875. PubMed DOI PMC
Chen R., Tang L., Sun T., Zeng Z., Zhang Y., Ding K., Meng Q. Mechanism and management of fentanyl-induced cough. Front. Pharmacol. 2020;11 https://www.frontiersin.org/articles/10.3389/fphar.2020.584177 PubMed DOI PMC
Bohn L.M., Lefkowitz R.J., Gainetdinov R.R., Peppel K., Caron M.G., Lin F.-T. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science. 1999;286:2495–2498. doi: 10.1126/science.286.5449.2495. PubMed DOI
Raehal K.M., Walker J.K.L., Bohn L.M. Morphine side effects in β-arrestin 2 knockout mice. J. Pharmacol. Exp. Therapeut. 2005;314:1195–1201. doi: 10.1124/jpet.105.087254. PubMed DOI
Zhang L., Zhang J.-T., Hang L., Liu T. Mu opioid receptor heterodimers emerge as novel therapeutic targets: recent progress and future perspective. Front. Pharmacol. 2020;11 https://www.frontiersin.org/articles/10.3389/fphar.2020.01078 PubMed DOI PMC
Zhou J., Ma R., Jin Y., Fang J., Du J., Shao X., Liang Y., Fang J. Molecular mechanisms of opioid tolerance: from opioid receptors to inflammatory mediators (Review) Exp. Ther. Med. 2021;22:1–8. doi: 10.3892/etm.2021.10437. PubMed DOI PMC
Martyn J.A.J., Mao J., Bittner E.A. Opioid tolerance in critical illness. N. Engl. J. Med. 2019;380:365–378. doi: 10.1056/NEJMra1800222. PubMed DOI PMC
Comer S.D., Cahill C.M. Fentanyl: receptor pharmacology, abuse potential, and implications for treatment. Neurosci. Biobehav. Rev. 2019;106:49–57. doi: 10.1016/j.neubiorev.2018.12.005. PubMed DOI PMC
Ricarte A., Dalton J.A.R., Giraldo J. Structural assessment of agonist efficacy in the μ-opioid receptor: morphine and fentanyl elicit different activation patterns. J. Chem. Inf. Model. 2021;61:1251–1274. doi: 10.1021/acs.jcim.0c00890. PubMed DOI
de Waal P.W., Shi J., You E., Wang X., Melcher K., Jiang Y., Xu H.E., Dickson B.M. Molecular mechanisms of fentanyl mediated β-arrestin biased signaling. PLoS Comput. Biol. 2020;16 doi: 10.1371/journal.pcbi.1007394. PubMed DOI PMC
Ramos-Matos C.F., Bistas K.G., Lopez-Ojeda W. StatPearls Publishing; Treasure Island (FL): 2022. Fentanyl, in: StatPearls.http://www.ncbi.nlm.nih.gov/books/NBK459275/ PubMed
Kuip E.J.M., Zandvliet M.L., Koolen S.L.W., Mathijssen R.H.J., van der Rijt C.C.D. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. Br. J. Clin. Pharmacol. 2017;83:294–313. doi: 10.1111/bcp.13129. PubMed DOI PMC
Grape S., Schug S.A., Lauer S., Schug B.S. Formulations of fentanyl for the management of pain. Drugs. 2010;70:57–72. doi: 10.2165/11531740-000000000-00000. PubMed DOI
Ziesenitz V.C., König S.K., Mahlke N.S., Skopp G., Haefeli W.E., Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J. Clin. Pharmacol. 2015;55:708–717. doi: 10.1002/jcph.469. PubMed DOI
Wilde M., Pichini S., Pacifici R., Tagliabracci A., Busardò F.P., Auwärter V., Solimini R. Metabolic pathways and potencies of new fentanyl analogs. Front. Pharmacol. 2019;10 https://www.frontiersin.org/articles/10.3389/fphar.2019.00238 PubMed DOI PMC
Schwartz R.B., McCollum D. In: Roberts and Hedges' Clinical Procedures in Emergency Medicine and Acute Care. seventh ed. Roberts J.R., Custalow C.B., Thomsen T.W., editors. Elsevier; Philadelphia, PA: 2019. Chapter 5: pharmacologic adjuncts to intubation; pp. 111–126.
Kiyatkin E.A. Respiratory depression and brain hypoxia induced by opioid drugs: morphine, oxycodone, heroin, and fentanyl. Neuropharmacology. 2019;151:219–226. doi: 10.1016/j.neuropharm.2019.02.008. PubMed DOI PMC
DRUGS, fentanyl: uses, dosage, side effects & warnings. 2022. https://www.drugs.com/fentanyl.html
Vardanyan R.S., Hruby V.J. Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications. Future Med. Chem. 2014;6:385–412. doi: 10.4155/fmc.13.215. PubMed DOI PMC
DEA, fentanyl. 2022. https://www.dea.gov/factsheets/fentanyl
Joranson D.E., Ryan K.M., Gilson A.M., Dahl J.L. Trends in medical use and abuse of opioid analgesics. JAMA. 2000;283:1710–1714. doi: 10.1001/jama.283.13.1710. PubMed DOI
Booth J.V., Grossman D., Moore J., Lineberger C., Reynolds J.D., Reves J.G., Sheffield D. Substance abuse among physicians: a survey of academic anesthesiology programs. Anesth. Analg. 2002;95:1024–1030. doi: 10.1097/00000539-200210000-00043. table of contents. PubMed DOI
Darke S., Duflou J. The toxicology of heroin-related death: estimating survival times. Addiction. 2016;111:1607–1613. doi: 10.1111/add.13429. PubMed DOI
Somerville N., O'Donnell J., Gladden R., Zibbell J., Green T., Younkin M., Ruiz S., Babakhanlou-Chase H., Chan M., Callis B., Kuramoto-Crawford J., Nields H., Walley A. Characteristics of fentanyl overdose - Massachusetts, 2014-2016. MMWR (Morb. Mortal. Wkly. Rep.) 2017;66:382–386. doi: 10.15585/mmwr.mm6614a2. PubMed DOI PMC
Ciccarone D., Ondocsin J., Mars S.G. Heroin uncertainties: exploring users' perceptions of fentanyl-adulterated and -substituted ‘heroin. Int. J. Drug Pol. 2017;46:146–155. doi: 10.1016/j.drugpo.2017.06.004. PubMed DOI PMC
CDC Reported law enforcement encounters testing positive for fentanyl increase across US. 2022. https://www.cdc.gov/drugoverdose/deaths/fentanyl-encounters/index.html
O'Donnell J. Notes from the field: opioid-involved overdose deaths with fentanyl or fentanyl analogs detected — 28 states and the District of Columbia, july 2016–december 2018. MMWR Morb. Mortal. Wkly. Rep. 2020;69:271–273. doi: 10.15585/mmwr.mm6910a4. PubMed DOI PMC
Moss R.B., Carlo D.J. Higher doses of naloxone are needed in the synthetic opioid era. Subst. Abuse Treat. Prev. Pol. 2019;14:6. doi: 10.1186/s13011-019-0195-4. PubMed DOI PMC
Wang S. Historical review: opiate addiction and opioid receptors. Cell Transplant. 2019;28:233–238. doi: 10.1177/0963689718811060. PubMed DOI PMC
Rzasa Lynn R., Galinkin J. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9:63–88. doi: 10.1177/2042098617744161. PubMed DOI PMC
Varshneya N.B., Hassanien S.H., Holt M.C., Stevens D.L., Layle N.K., Bassman J.R., Iula D.M., Beardsley P.M. Fentanyl analog structure-activity relationships demonstrate determinants of diverging potencies for antinociception and respiratory depression. Pharmacol. Biochem. Behav. 2023;226 doi: 10.1016/j.pbb.2023.173572. PubMed DOI PMC
Varshneya N.B., Walentiny D.M., Moisa L.T., Walker T.D., Akinfiresoye L.R., Beardsley P.M. Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances. Neuropharmacology. 2019;151:171–179. doi: 10.1016/j.neuropharm.2019.03.023. PubMed DOI PMC
Janssen P.A.J., Gordocki J.F. 1964. Method for Producing Analgesia. US3141823A.
Higashikawa Y., Suzuki S. Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and its related compounds. VI. Structure-analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues. Forensic Toxicol. 2008;26:1–5. doi: 10.1007/s11419-007-0039-1. DOI
Walker E.A., Chambers C., Korber M.G., Tella S.R., Prioleau C., Fang L. Antinociceptive and discriminative stimulus effects of six novel psychoactive opioid substances in male rats. J. Pharmacol. Exp. Therapeut. 2021;379:1–11. doi: 10.1124/jpet.121.000689. PubMed DOI PMC
Prekupec M.P., Mansky P.A., Baumann M.H. Misuse of novel synthetic opioids: a deadly new trend. J. Addiction Med. 2017;11:256–265. doi: 10.1097/ADM.0000000000000324. PubMed DOI PMC
Watanabe S., Vikingsson S., Roman M., Green H., Kronstrand R., Wohlfarth A. In vitro and in vivo metabolite identification studies for the new synthetic opioids acetylfentanyl, acrylfentanyl, furanylfentanyl, and 4-fluoro-isobutyrylfentanyl. AAPS J. 2017;19:1102–1122. doi: 10.1208/s12248-017-0070-z. PubMed DOI
Stogner J.M. The potential threat of acetyl fentanyl: legal issues, contaminated heroin, and acetyl fentanyl “disguised” as other opioids. Ann. Emerg. Med. 2014;64:637–639. doi: 10.1016/j.annemergmed.2014.07.017. PubMed DOI
McIntyre I.M., Trochta A., Gary R.D., Malamatos M., Lucas J.R. An acute acetyl fentanyl fatality: a case report with postmortem concentrations. J. Anal. Toxicol. 2015;39:490–494. doi: 10.1093/jat/bkv043. PubMed DOI
Pearson J., Poklis J., Poklis A., Wolf C., Mainland M., Hair L., Devers K., Chrostowski L., Arbefeville E., Merves M. Postmortem toxicology findings of acetyl fentanyl, fentanyl, and morphine in heroin fatalities in tampa, Florida. Acad Forensic Pathol. 2015;5:676–689. doi: 10.23907/2015.072. PubMed DOI PMC
Cunningham S.M., Haikal N.A., Kraner J.C. Fatal intoxication with acetyl fentanyl. J. Forensic Sci. 2016;61(Suppl 1):S276–S280. doi: 10.1111/1556-4029.12953. PubMed DOI
EMCDDA Europol, Acetylfentanyl: EMCDA-Europol joint report on a new psychoactive substance: N-phenyl-N-1-(2-phenylethyl)piperidin-4-ylacetamide (acetylfentanyl): in accordordance with Article 5 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. 2016. https://data.europa.eu/doi/10.2810/890694 DOI
Guerrieri D., Rapp E., Roman M., Thelander G., Kronstrand R. Acrylfentanyl: another new psychoactive drug with fatal consequences. Forensic Sci. Int. 2017;277:e21–e29. doi: 10.1016/j.forsciint.2017.05.010. PubMed DOI
Melent’ev A.B., Kataev S.S., Dvorskaya O.N. Identification and analytical properties of acetyl fentanyl metabolites. J. Anal. Chem. 2015;70:240–248. doi: 10.1134/S1061934815020124. DOI
Miller J.M., Stogner J.M., Miller B.L., Blough S. Exploring synthetic heroin: accounts of acetyl fentanyl use from a sample of dually diagnosed drug offenders. Drug Alcohol Rev. 2018;37:121–127. doi: 10.1111/dar.12502. PubMed DOI
Ujváry I., Jorge R., Christie R., Le Ruez T., Danielsson H.V., Kronstrand R., Elliott S., Gallegos A., Sedefov R., Evans-Brown M. Acryloylfentanyl, a recently emerged new psychoactive substance: a comprehensive review. Forensic Toxicol. 2017;35:232–243. doi: 10.1007/s11419-017-0367-8. DOI
Zhu Y.Q., Ge G.L., Fang S.N., Zhu Y.C., Dai Q.Y., Tan Z.Y., Huang Z.M., Chen X.J. [Studies on potent analgesics. I. Synthesis and analgesic activity of derivatives of fentanyl (author's transl)] Yao Xue Xue Bao. 1981;16:199–210. PubMed
Essawi M.Y. Fentanyl analogues with a modified propanamido group as potential affinity labels: synthesis and in vivo activity. Pharmazie. 1999;54:307–308. PubMed
Bilel S., Azevedo Neto J., Arfè R., Tirri M., Gaudio R.M., Fantinati A., Bernardi T., Boccuto F., Marchetti B., Corli G., Serpelloni G., De-Giorgio F., Malfacini D., Trapella C., Calo G., Marti M. In vitro and in vivo pharmaco-dynamic study of the novel fentanyl derivatives: acrylfentanyl, Ocfentanyl and Furanylfentanyl. Neuropharmacology. 2022;209 doi: 10.1016/j.neuropharm.2022.109020. PubMed DOI
Butler D.C., Shanks K., Behonick G.S., Smith D., Presnell S.E., Tormos L.M. Three cases of fatal acrylfentanyl toxicity in the United States and a review of literature. J. Anal. Toxicol. 2018;42:e6–e11. doi: 10.1093/jat/bkx083. PubMed DOI
EMCDDA, Acryloylfentanyl Report on the risk assessment of N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl) in the framework of the Council Decision on new psychoactive substances. 2017. https://data.europa.eu/doi/10.2810/252346 DOI
Baumann M.H., Majumdar S., Le Rouzic V., Hunkele A., Uprety R., Huang X.P., Xu J., Roth B.L., Pan Y.-X., Pasternak G.W. Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology. 2018;134:101–107. doi: 10.1016/j.neuropharm.2017.08.016. PubMed DOI PMC
Kanamori T., Iwata Y.T., Segawa H., Yamamuro T., Kuwayama K., Tsujikawa K., Inoue H. Metabolism of butyrylfentanyl in fresh human hepatocytes: chemical synthesis of authentic metabolite standards for definitive identification. Biol. Pharm. Bull. 2019;42:623–630. doi: 10.1248/bpb.b18-00765. PubMed DOI
Mörén L., Lindén P., Qvarnström J., Engqvist M., Carlsson M., Afshin Sander R., Lindberg S., Larsson A., Östin A. Classification of carfentanil synthesis methods based on chemical impurity profile. Forensic Chemistry. 2021;26 doi: 10.1016/j.forc.2021.100355. DOI
Van Bever W.F., Niemegeers C.J., Janssen P.A. Synthetic analgesics. Synthesis and pharmacology of the diastereoisomers of N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide and N-(3-methyl-1-(1-methyl-2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. J. Med. Chem. 1974;17:1047–1051. doi: 10.1021/jm00256a003. PubMed DOI
Kukanich B., Papich M. In: Veterinary Pharmacology and Therapeutics. ninth ed. Riviere E., Papich M.G., Adams H.R., editors. Wiley-Blackwell; Hoboken, NJ: 2009. Opioid analgesic drugs; pp. 301–337.
Wong B., Perkins M.W., Tressler J., Rodriguez A., Devorak J., Sciuto A.M. Effects of inhaled aerosolized carfentanil on real-time physiological responses in mice: a preliminary evaluation of naloxone. Inhal. Toxicol. 2017;29:65–74. doi: 10.1080/08958378.2017.1282065. PubMed DOI
Bergh M.S.-S., Bogen I.L., Garibay N., Baumann M.H. Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats. Neuropharmacology. 2019;158 doi: 10.1016/j.neuropharm.2019.04.002. PubMed DOI PMC
EMCDDA, Carfentanil Report on the risk assessment of methyl 1-(2-phenylethyl)-4-phenyl(propanoyl)aminopiperidine-4-carboxylate in the framework of the Council Decision on new psychoactive substances. 2018. https://data.europa.eu/doi/10.2810/411341 DOI
Riches J.R., Read R.W., Black R.M., Cooper N.J., Timperley C.M. Analysis of clothing and urine from Moscow theatre siege casualties reveals carfentanil and remifentanil use. J. Anal. Toxicol. 2012;36:647–656. doi: 10.1093/jat/bks078. PubMed DOI
Åstrand A., Töreskog A., Watanabe S., Kronstrand R., Gréen H., Vikingsson S. Correlations between metabolism and structural elements of the alicyclic fentanyl analogs cyclopropyl fentanyl, cyclobutyl fentanyl, cyclopentyl fentanyl, cyclohexyl fentanyl and 2,2,3,3-tetramethylcyclopropyl fentanyl studied by human hepatocytes and LC-QTOF-MS. Arch. Toxicol. 2019;93:95–106. doi: 10.1007/s00204-018-2330-9. PubMed DOI PMC
Helander A., Bäckberg M., Signell P., Beck O. Intoxications involving acrylfentanyl and other novel designer fentanyls - results from the Swedish STRIDA project. Clin. Toxicol. 2017;55:589–599. doi: 10.1080/15563650.2017.1303141. PubMed DOI
Janssen P.A.J. 1965. 1-aralkyl-4-(n-aryl-carbonyl Amino)-Piperidines and Related Compounds.https://patents.google.com/patent/US3164600A/en US3164600A.
Lipiński P.F.J., Kosson P., Matalińska J., Roszkowski P., Czarnocki Z., Jarończyk M., Misicka A., Dobrowolski J.Cz, Sadlej J. Fentanyl family at the mu-opioid receptor: uniform assessment of binding and computational analysis. Molecules. 2019;24:740. doi: 10.3390/molecules24040740. PubMed DOI PMC
Bergh M.S.-S., Bogen I.L., Garibay N., Baumann M.H. Pharmacokinetics and pharmacodynamics of cyclopropylfentanyl in male rats. Psychopharmacology. 2021;238:3629–3641. doi: 10.1007/s00213-021-05981-x. PubMed DOI PMC
Xie B., Le Rouzic V.P., Goldberg A., Tsai M.-H.M., Chen L., Zhang T., Sinha A., Pan Y.-X., Baumann M.H., Shi L. Binding preference at the μ-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl. Neuropharmacology. 2023;227 doi: 10.1016/j.neuropharm.2023.109442. PubMed DOI PMC
EMCDDA Europol, Cyclopropylfentanyl: EMCDDA–Europol joint report on a new psychoactive substance: N-phenyl-N-1-(2-phenylethyl)piperidin-4-ylcyclopropanecarboxamide (cyclopropylfentanyl): in accordance with Article 5 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. 2018. https://data.europa.eu/doi/10.2810/06909 DOI
EMCDDA Two new synthetic opioids to be placed under control across the EU. 2018. https://www.emcdda.europa.eu/news/2018/6/council-implementing-decision-to-control-cyclopropylfentanyl-and-methoxyacetylfentanyl_en
Poklis J., Poklis A., Wolf C., Hathaway C., Arbefeville E., Chrostowski L., Devers K., Hair L., Mainland M., Merves M., Pearson J. Two fatal intoxications involving butyryl fentanyl. J. Anal. Toxicol. 2016;40:703–708. doi: 10.1093/jat/bkw048. PubMed DOI PMC
Vohra V., Hodgman M., Marraffa J., Barba K., Stoppacher R. Fentanyl- and fentanyl analog-related deaths across five counties in Central New York between 2013 and 2017. Clin. Toxicol. 2020;58:112–116. doi: 10.1080/15563650.2019.1613548. PubMed DOI
Brunetti P., Pirani F., Carlier J., Giorgetti R., Busardò F.P., Lo Faro A.F. A 2017-2019 update on acute intoxications and fatalities from illicit fentanyl and analogs. J. Anal. Toxicol. 2021;45:537–554. doi: 10.1093/jat/bkaa115. PubMed DOI
Rojkiewicz M., Majchrzak M., Celiński R., Kuś P., Sajewicz M. Identification and physicochemical characterization of 4-fluorobutyrfentanyl (1-((4-fluorophenyl)(1-phenethylpiperidin-4-yl)amino)butan-1-one, 4-FBF) in seized materials and post-mortem biological samples. Drug Test. Anal. 2017;9:405–414. doi: 10.1002/dta.2135. PubMed DOI
Gundersen P.O.M., Åstrand A., Gréen H., Josefsson M., Spigset O., Vikingsson S. Metabolite profiling of ortho-, meta- and para-fluorofentanyl by hepatocytes and high-resolution mass spectrometry. J. Anal. Toxicol. 2019;44:140–148. doi: 10.1093/jat/bkz081. PubMed DOI PMC
Helland A., Brede W.R., Michelsen L.S., Gundersen P.O.M., Aarset H., Skjølås J.E., Slørdal L. Two hospitalizations and one death after exposure to ortho-fluorofentanyl. J. Anal. Toxicol. 2017;41:708–709. doi: 10.1093/jat/bkx050. PubMed DOI
Huang B.-S., Terrell R.C., Deutsche K.H., Kudzma L.V., Lalinde N.L. 1986. N-aryl-N-(4-piperidinyl)amides and Pharmaceutical Compositions and Method Employing Such Compounds. US4584303A.
EMCDDA Europol, Furanylfentanyl: EMCDDA–Europol joint report on a new psychoactive substance: N-phenyl-N-1-(2-phenylethyl)piperidin-4-yl-furan-2-carboxamide (furanylfentanyl): in accordance with Article 5 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. 2017. https://data.europa.eu/doi/10.2810/83192 DOI
Li L., Yu X., Lyu L., Duan H., Chen Y., Bian J., Xu Z., Liu L., Zhang Y. Determination of fentanyl, alpha-methylfentanyl, beta-hydroxyfentanyl and the metabolite norfentanyl in rat urine by LC-MS-MS. J. Anal. Toxicol. 2022;46:421–431. doi: 10.1093/jat/bkab021. PubMed DOI
Hendrickson R.G., Akpunonu P., Hughes A.R., Gerona R. Highly potent fentanyl analogs: apnea from exposure to small quantities of ß-hydroxyfentanyl and furanylfentanyl. Clin. Toxicol. 2019;57:813–815. doi: 10.1080/15563650.2018.1558233. PubMed DOI
DPS Emergency controlled substance scheduling action. 2016. https://dps.hawaii.gov/wp-content/uploads/2016/05/Emergency-Controlled-Substance-Scheduling-Action-05-18-2016.pdf
Kahl J.H., Gonyea J., Humphrey S.M., Hime G.W., Boland D.M. Quantitative analysis of fentanyl and six fentanyl analogs in postmortem specimens by UHPLC-MS-MS. J. Anal. Toxicol. 2018;42:570–580. doi: 10.1093/jat/bky054. PubMed DOI
Bagley J.R., Kudzma L.V., Lalinde N.L., Colapret J.A., Huang B.S., Lin B.S., Jerussi T.P., Benvenga M.J., Doorley B.M., Ossipov M.H. Evolution of the 4-anilidopiperidine class of opioid analgesics. Med. Res. Rev. 1991;11:403–436. doi: 10.1002/med.2610110404. PubMed DOI
Vasudevan L., Vandeputte M., Deventer M., Wouters E., Cannaert A., Stove C.P. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform. Biochem. Pharmacol. 2020;177 doi: 10.1016/j.bcp.2020.113910. PubMed DOI
Mardal M., Johansen S.S., Davidsen A.B., Telving R., Jornil J.R., Dalsgaard P.W., Hasselstrøm J.B., Øiestad Å.M., Linnet K., Andreasen M.F. Postmortem analysis of three methoxyacetylfentanyl-related deaths in Denmark and in vitro metabolite profiling in pooled human hepatocytes. Forensic Sci. Int. 2018;290:310–317. doi: 10.1016/j.forsciint.2018.07.020. PubMed DOI
EMCDDA Methoxyacetylfentanyl, report on the risk assessment of 2-methoxy-N-phenyl-N-1-(2-phenylethyl)piperidin-4-ylacetamide in the framework of the Council Decision on new psychoactive substances. 2018;30:1–58. https://data.europa.eu/doi/10.2810/520464 (Accessed 30 October 2022) DOI
Gillespie T.J., Gandolfi A.J., Davis T.P., Morano R.A. Identification and quantification of alpha-methylfentanyl in post mortem specimens. J. Anal. Toxicol. 1982;6:139–142. doi: 10.1093/jat/6.3.139. PubMed DOI
Higashikawa Y., Suzuki S. Studies on 1-(2-phenethyl)-4-(N-Propionylanilino)Piperidine (fentanyl) and its related compounds: novel metabolites in rat urine following injection of α-methylfentanyl, one of the most abused typical designer drugs. J. Health Sci. 2008;54:629–637. doi: 10.1248/jhs.54.629. DOI
Sato S., Suzuki S., Lee X.-P., Sato K. Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and related compounds: VII. Quantification of α-methylfentanyl metabolites excreted in rat urine. Forensic Sci. Int. 2010;195:68–72. doi: 10.1016/j.forsciint.2009.11.014. PubMed DOI
UNODC Recommended methods for the identification and analysis of fentanyl and its analogues in biological specimens. 2017. www.unodc.org/unodc/en/scientists/recommended-methods-for-the-identification-and-analysis-of-fentanyl-and-its-analogues-in-biological-specimens.html
Kanamori T., Okada Y., Segawa H., Yamamuro T., Kuwayama K., Tsujikawa K., Iwata Y.T. Evaluation of agonistic activity of fluorinated and nonfluorinated fentanyl analogs on μ-opioid receptor using a cell-based assay system. Biol. Pharm. Bull. 2021;44:159–161. doi: 10.1248/bpb.b20-00780. PubMed DOI
Allibe N., Richeval C., Phanithavong M., Faure A., Allorge D., Paysant F., Stanke-Labesque F., Eysseric-Guerin H., Gaulier J.-M. Fatality involving ocfentanil documented by identification of metabolites. Drug Test. Anal. 2018;10:995–1000. doi: 10.1002/dta.2326. PubMed DOI
Coopman V., Cordonnier J., De Leeuw M., Cirimele V. Ocfentanil overdose fatality in the recreational drug scene. Forensic Sci. Int. 2016;266:469–473. doi: 10.1016/j.forsciint.2016.07.005. PubMed DOI
Dussy F.E., Hangartner S., Hamberg C., Berchtold C., Scherer U., Schlotterbeck G., Wyler D., Briellmann T.A. An acute ocfentanil fatality: a case report with postmortem concentrations. J. Anal. Toxicol. 2016;40:761–766. doi: 10.1093/jat/bkw096. PubMed DOI
Hassanien S.H., Bassman J.R., Perrien Naccarato C.M., Twarozynski J.J., Traynor J.R., Iula D.M., Anand J.P. In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis. Drug Test. Anal. 2020;12:1212–1221. doi: 10.1002/dta.2822. PubMed DOI PMC
Krotulski A.J., Papsun D.M., Friscia M., Swartz J.L., Holsey B.D., Logan B.K. Fatality following ingestion of tetrahydrofuranylfentanyl, U-49900 and methoxy-phencyclidine. J. Anal. Toxicol. 2018;42:e27–e32. doi: 10.1093/jat/bkx092. PubMed DOI
EMCDDA, THF-F Report on the risk assessment of N-phenyl-N-1-(2-phenylethyl)piperidin-4-yloxolane-2-carboxamide in the framework of the Council Decision on new psychoactive substances. 2018. https://data.europa.eu/doi/10.2810/097948 DOI
Cooman T., Hoover B., Sauvé B., Bergeron S.A., Quinete N., Gardinali P., Arroyo L.E. The metabolism of valerylfentanyl using human liver microsomes and zebrafish larvae. Drug Test. Anal. 2022;14:1116–1129. doi: 10.1002/dta.3233. PubMed DOI
Ton E., Stevens C., Moorman P., Markey M., Hunter B., Bush R., Jones P. Thirteen cases of valeryl fentanyl in Michigan: a call for expanding opioid testing. Am. J. Forensic Med. Pathol. 2021;42:367–372. doi: 10.1097/PAF.0000000000000722. PubMed DOI
Skulska A., Kała M., Parczewski A. Fentanyl and its analogues in the forensic laboratory. Medical and analytical problems. Z Zagadnień Nauk Sądowych. 2004;59:127–142.
Misailidi N., Papoutsis I., Nikolaou P., Dona A., Spiliopoulou C., Athanaselis S. Fentanyls continue to replace heroin in the drug arena: the cases of ocfentanil and carfentanil. Forensic Toxicol. 2018;36:12–32. doi: 10.1007/s11419-017-0379-4. PubMed DOI PMC
Yu L. Reference Module in Biomedical Sciences. Elsevier; 2014. Opioids. DOI
O'Donnell J., Tanz L.J., Gladden R.M., Davis N.L., Bitting J. Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls — United States, 2019–2020. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1740–1746. doi: 10.15585/mmwr.mm7050e3. PubMed DOI PMC
DeWeerdt S. Tracing the US opioid crisis to its roots. Nature. 2019;573:S10–S12. doi: 10.1038/d41586-019-02686-2. PubMed DOI
Santoro T.N., Santoro J.D. Racial bias in the US opioid epidemic: a review of the history of systemic bias and implications for care. Cureus. 2018;10 doi: 10.7759/cureus.3733. PubMed DOI PMC
Hedegaard H., Miniño A.M., Warner M. NCHS Data Brief; 2020. Drug Overdose Deaths in the United States, 1999–2019; p. 8. PubMed
van Amsterdam J., Pierce M., van den Brink W. Is Europe facing an emerging opioid crisis comparable to the U.S. Ther. Drug Monit. 2021;43:42–51. doi: 10.1097/FTD.0000000000000789. PubMed DOI
Pilch R., Dolnik A. The Moscow Theater hostage crisis: the perpetrators, their tactics, and the Russian response. Int. Negot. 2003;8:577–611. doi: 10.1163/1571806031310798. DOI
Kirk R. Chicago Review Press; 2022. Righting Wrongs: 20 Human Rights Heroes Around the World.
Crowley M., Dando M. The use of incapacitating chemical agent weapons in law enforcement. Int. J. Hum. Right. 2015;19:465–487. doi: 10.1080/13642987.2015.1027064. DOI
CDC Emergency response safety and health database: glossary. 2021. https://www.cdc.gov/niosh/ershdb/glossary.html
Kuča K., Pohanka M. In: Molecular, Clinical and Environmental Toxicology: Volume 2: Clinical Toxicology. Luch A., editor. Birkhäuser; Basel: 2010. Chemical warfare agents; pp. 543–558. DOI
Lee D., Kulkarni R.G. In: Ciottone's Disaster Medicine. second ed. Ciottone G.R., editor. Elsevier; Philadelphia: 2016. Chapter 118 - opioid agent attack; pp. 677–679. DOI
Tin D., Kallenborn Z., Hart A., Hertelendy A.J., Ciottone G.R. Opioid attack and the implications for counter-terrorism medicine. Prehospital Disaster Med. 2021;36:661–663. doi: 10.1017/S1049023X21001059. PubMed DOI
Pearson A. Incapacitating biochemical weapons. Nonproliferation Rev. 2006;13:151–188. doi: 10.1080/10736700601012029. DOI
Tennesse State Government Attorney general skrmetti urges president biden to classify fentanyl as a weapon of mass destruction. 2022. https://www.tn.gov/attorneygeneral/news/2022/9/15/pr22-35.html
Lorch U., Pierscionek T., Freier A., Spencer C.S., Täubel J. Safety, tolerability, and dose proportionality of a novel transdermal fentanyl matrix patch and bioequivalence with a matrix fentanyl patch: two phase 1 single-center open-label, randomized crossover studies in healthy Japanese volunteers. Clin Pharmacol Drug Dev. 2021;10:260–271. doi: 10.1002/cpdd.846. PubMed DOI PMC
Geile J., Maas A., Kraemer M., Doberentz E., Madea B. Fatal misuse of transdermal fentanyl patches. Forensic Sci. Int. 2019;302 doi: 10.1016/j.forsciint.2019.06.016. PubMed DOI
Lampert A., Haefeli W.E., Seidling H.M. [Information gaps in package inserts cause insufficient patient information on correct handling of transdermal patches] Dtsch. Med. Wochenschr. 2019;144:e36–e41. doi: 10.1055/a-0722-7419. PubMed DOI
Nara A., Yamada C., Saka K., Kodama T., Yoshida M., Iwahara K., Takagi T. A fatal case of poisoning with fentanyl transdermal patches in Japan. J. Forensic Sci. 2019;64:1936–1942. doi: 10.1111/1556-4029.14127. PubMed DOI
Jost U., Wolter E., Böhrer H. [Repeated improper intravenous injection of fentanyl from a transdermal system] Dtsch. Med. Wochenschr. 2004;129:313–314. doi: 10.1055/s-2004-818627. PubMed DOI
Kimergård A., Dunne J., Bøgen A., Hindersson P., Breindahl T. Characteristics of opioid-maintained clients smoking fentanyl patches: the importance of confirmatory drug analysis illustrated by a case series and mini-review. Drug Test. Anal. 2018;10:917–926. doi: 10.1002/dta.2397. PubMed DOI
Padula C., Pescina S., Nicoli S., Santi P. Generic patches containing fentanyl: in vitro equivalence and abuse deterrent evaluation according to EMA and FDA guidelines. Int. J. Pharm. 2018;537:57–63. doi: 10.1016/j.ijpharm.2017.12.031. PubMed DOI
Kirane H., Drits E., Ahn S., Kapoor S., Morgenstern J., Conigliaro J., Enden J. Addressing the opioid crisis: an assessment of clinicians' training experience, practices, and attitudes within a large healthcare organization. J Opioid Manag. 2019;15:193–204. doi: 10.5055/jom.2019.0503. PubMed DOI
Abonamah J.V., Eckenrode B.A., Moini M. On-site detection of fentanyl and its derivatives by field portable nano-liquid chromatography-electron lonization-mass spectrometry (nLC-EI-MS) Forensic Chemistry. 2019;16 doi: 10.1016/j.forc.2019.100180. DOI